Funder
Shanghai Junshi Biosciences
Reference23 articles.
1. The forgotten lipids: triglycerides, remnant cholesterol, and atherosclerotic cardiovascular disease risk;Sandesara;Endocr Rev,2019
2. Chinese guidelines for lipid management (2023);Chin J Cardiol,2023
3. Pooled safety analysis of evolocumab in over 6000 patients from double-blind and open-label extension studies;Toth;Circulation,2017
4. Efficacy and safety of more intensive lowering of LDL cholesterol: a meta-analysis of data from 170,000 participants in 26 randomised trials;Baigent;Lancet (London, England),2010
5. Efficacy and safety of alirocumab vs ezetimibe in statin-intolerant patients, with a statin rechallenge arm: the ODYSSEY ALTERNATIVE randomized trial;Moriarty;J Clin Lipidol,2015